Monoclonal antibodies companies
Companies whose enriched business profile is tagged “Monoclonal antibodies”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + Finnhub, shown with its as-of date.
- Amgen (AMGN) Health Care — A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. ask →
- Regeneron Pharmaceuticals (REGN) Health Care — Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas. ask →
- SPYRE THERAPEUTICS INC (SYRE) Health Care — Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases with potential for quarterly dosing convenience. ask →
- MIRUM PHARMACEUTICALS INC (MIRM) Health Care — Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis. ask →
- SCHOLAR ROCK HOLDING CORP (SRRK) Health Care — Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026. ask →
- Ultragenyx (RARE) Health Care — A biopharmaceutical company developing and commercializing novel therapies for rare and ultra-rare genetic diseases with high unmet medical need. ask →
- VIRIDIAN THERAPEUTICS ORS INC (VRDN) Health Care — Viridian is a clinical-stage biopharmaceutical company developing potentially differentiated monoclonal antibody therapies for thyroid eye disease and autoimmune diseases, with lead candidate veligrotug advancing through late-stage trials against Amgen's Tepezza. ask →
- CLIMB BIO INC (CLYM) Health Care — Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and lupus. ask →
- SHATTUCK LABS INC (STTK) Health Care — A clinical-stage biotech pioneering potentially first-in-class DR3 blocking antibodies to treat inflammatory bowel disease and other immune-mediated diseases. ask →
- PROTHENA PLC (PRTA) Health Care — A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through proprietary CYTOPE® intracellular delivery technology, in partnership with major pharma. ask →
Not quite it? Describe exactly what you want →
Data: SEC EDGAR (filings) + Finnhub (fundamentals, delayed daily-close). Figures shown with their as-of date.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.